Trump touted a drug's effectiveness against coronavirus. Now its manufacturer is overwhelmed by demand.
President Trump has promoted a few different drugs as effective remedies against the novel coronavirus in recent days, but demand for one of them has become so overwhelming that its manufacturer has temporarily shut down its emergency access program to build a broader one, The New York Times reports.
Gilead, which produces remdesivir, a drug that's being studied in large-scale clinical trials across the globe and is currently administered in certain coronavirus cases, said it can no longer grant compassionate use requests because it can't keep up with the number coming in. The company said its emergency access program was limited and never intended for a pandemic, but now that the world is facing one, Gilead intends to set up a broader access program to help more people. "This approach will both accelerate access to remdesivir for severely ill patients and enable the collection of data from all participating patients," the company said in a statement.
In the meantime, though, the Times reports some people said the decision means ill patients with few options will have to face delays.
Subscribe to The Week
Escape your echo chamber. Get the facts behind the news, plus analysis from multiple perspectives.
Sign up for The Week's Free Newsletters
From our morning news briefing to a weekly Good News Newsletter, get the best of The Week delivered directly to your inbox.
From our morning news briefing to a weekly Good News Newsletter, get the best of The Week delivered directly to your inbox.
It's not clear how effective remdesivir is against COVID-19 on a large scale, but the trials underway in China should deliver some sense of its prowess by the end of April. Read more at The New York Times.
Sign up for Today's Best Articles in your inbox
A free daily email with the biggest news stories of the day – and the best features from TheWeek.com
Tim is a staff writer at The Week and has contributed to Bedford and Bowery and The New York Transatlantic. He is a graduate of Occidental College and NYU's journalism school. Tim enjoys writing about baseball, Europe, and extinct megafauna. He lives in New York City.
-
Cautious optimism surrounds plans for the world's first nuclear fusion power plant
Talking Point Some in the industry feel that the plant will face many challenges
By Justin Klawans, The Week US Published
-
Explore new worlds this winter at these 6 enlightening museum exhibitions
The Week Recommends Discover the estrados of Spain and the connection between art and chess in various African countries
By Catherine Garcia, The Week US Published
-
2024: the year of Black country artists
In the Spotlight Beyoncé debuted 'Cowboy Carter' at the top of the country charts, shining a spotlight on artists like Shaboozey
By Theara Coleman, The Week US Published
-
Marty Makary: the medical contrarian who will lead the FDA
In the Spotlight What Johns Hopkins surgeon and commentator Marty Makary will bring to the FDA
By David Faris Published
-
California declares bird flu emergency
Speed Read The emergency came hours after the nation's first person with severe bird flu infection was hospitalized
By Rafi Schwartz, The Week US Published
-
Bird flu one mutuation from human threat, study finds
Speed Read A Scripps Research Institute study found one genetic tweak of the virus could enable its spread among people
By Peter Weber, The Week US Published
-
Dark chocolate tied to lower diabetes risk
Speed Read The findings were based on the diets of about 192,000 US adults over 34 years
By Peter Weber, The Week US Published
-
ACA opens 2025 enrollment, enters 2024 race
Speed Read Mike Johnson promises big changes to the Affordable Care Act if Trump wins the election
By Peter Weber, The Week US Published
-
McDonald's sued over E. coli linked to burger
Speed Read The outbreak has sickened at least 49 people in 10 states and left one dead
By Rafi Schwartz, The Week US Published
-
Long Covid: study shows damage to brain's 'control centre'
The Explainer Research could help scientists understand long-term effects of Covid-19 as well as conditions such as MS and dementia
By The Week UK Published
-
FDA OKs new Covid vaccine, available soon
Speed read The CDC recommends the new booster to combat the widely-circulating KP.2 strain
By Peter Weber, The Week US Published